Payoneer has stopped being priced as a standalone cross-border payments compounder. In June the board signed a cash merger with Nuvei, the Advent-owned acquirer, at a fixed bid that converts the residual claim into a closing-probability instrument with a long regulatory clock. The June quarter still shows the mix shift the public market used to debate: business-to-business volume accelerated again while marketplace collections barely grew. That operating story now sits underneath a take-private that withdraws guidance, suspends buybacks, and cancels earnings calls.
The tension is that core fee economics improved while reported profit flipped to a loss. Revenue excluding interest income rose at a double-digit pace even as float income compressed on lower rates. Adjusted earnings before interest, taxes, depreciation, and amortization excluding interest more than doubled, which is the cleanest read that transaction costs and mix are doing real work. Deal fees, higher research spend, and a jump in other financial expense pushed the quarter into the red. Customer funds still grew, so the interest hit is a yield story, not a balance runoff.
The share price now sits just under the cash bid of $7.40 after a run from the fifty-two-week low. Early Hart-Scott-Rodino clearance arrived in late July, which removes the United States antitrust waiting period but leaves a thick stack of money-transmitter and change-of-control licenses still open. The question that prices the residual claim is whether those approvals clear in time for a mid-next-year close, or whether a broken deal hands investors back a China-heavy, Amazon-exposed payments name with no guide and a frozen repurchase program.